After approving 3D printed medical devices, the US Food and Drug Administration has now given green light to the production of 3D-printed pill.
It is being said that the new drug which is dubbed Spritam was developed by Aprecia Pharmaceuticals to control seizures brought on by epilepsy and they claim that printing the drug means that they could pack up to 1,000 milligrams into an individual tablet, reported the BBC.
Further, the company also claimed that they have developed a separate technology known as ZipDose that makes high-dose medications easier to swallow.
According to experts, being able to 3D print a tablet offers the potential to create bespoke drugs based on the specific needs of patients, rather than having a one product fits all approach.
Talking about the approval, lecturer Mohamed Albed Alhnan said that for the last 50 years, tablets have been manufactured in factories and shipped to hospitals but for the first time this process would help them in producing tablets that are much closer to the patient.
He added that it would mean that medical institutions could adjust the dose for individual patients with just a simple tweak to the software before printing.
According to the organisation, Spritam will be launched in the first quarter of 2016.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
